The relationship between serum miR-21 levels and left atrium dilation in elderly patients with essential hypertension

[1]

Piskorz D. Hypertensive mediated organ damage and hypertension management. how to assess beneficial effects of antihypertensive treatments? High Blood Press Cardiovasc Prev 2020; 27: 9−17.

[2]

Kanar B, Ozben B, Kanar H S, et al. Left atrial volume changes are an early marker of end-organ damage in essential hypertension: A multidisciplinary approach to an old problem. Echocardiography 2017; 34: 1895−1902.

[3]

Hoit B D. Left atrial size and function: role in prognosis. J Am Coll Cardiol 2014; 63: 493−505.

[4] Stefanadis C, Dernellis J, Toutouzas P. A clinical appraisal of left atrial function. Eur Heart J 2001; 22: 22−36. doi: 10.1053/euhj.1999.2581 [5] Blume GG, Mcleod CJ, Barnes ME, et al. Left atrial function: physiology, assessment, and clinical implications. Eur J Echocardiogr 2011; 12: 421−430. doi: 10.1093/ejechocard/jeq175 [6] Kurt M, Wang J, Torre-Amione G, et al. Left atrial function in diastolic heart failure. Circ Cardiovasc Imaging 2009; 2: 10−15. doi: 10.1161/CIRCIMAGING.108.813071 [7] Kontaraki JE, Marketou ME, Zacharis EA, et al. Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension. J Hum Hypertens 2014; 28: 510−516. doi: 10.1038/jhh.2013.117 [8] Da Costa Martins P, De Windt LJ. MicroRNAs in control of cardiac hypertrophy. Cardiovasc Res 2012; 93: 563−572. doi: 10.1093/cvr/cvs013 [9]

Kumarswamy R, Thum T. Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 2013; 113: 676−689.

[10] Kontaraki JE, Marketou ME, Parthenakis FI, et al. Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension. J Am Soc Hypertens 2015; 9: 802−810. doi: 10.1016/j.jash.2015.07.013 [11] Fernandes T, Magalhães FC, Roque FR, et al. Exercise training prevents the microvascular rarefaction in hypertension balancing angiogenic and apoptotic factors: role of microRNAs-16, -21, and -126. Hypertension 2012; 59: 513−520. doi: 10.1161/HYPERTENSIONAHA.111.185801 [12] Park MY, Herrmann SM, Saad A, et al. Circulating and renal vein levels of microRNAs in patients with renal artery stenosis. Nephrol Dial Transplant 2015; 30: 480−490. doi: 10.1093/ndt/gfu341 [13] Romero DG, Plonczynski MW, Carvajal CA, et al. Microribonucleic acid-21 increases aldosterone secretion and proliferation in H295R human adrenocortical cells. Endocrinology 2008; 149: 2477−2483. doi: 10.1210/en.2007-1686 [14] Watanabe K, Narumi T, Watanabe T, et al. The association between microRNA-21 and hypertension-induced cardiac remodeling. PLoS One 2020; 15: e0226053. doi: 10.1371/journal.pone.0226053 [15]

Society Hypertension Branch of Chinese Geriatrics National Clinical Research Center for Geriatric Diseases - Chinese Alliance of Geriatric Cardiovascular Disease, 2019 Chinese guidelines for the management of hypertension in the elderly. Chin J Cardiovasc Med 2019; 6: 1-27.

[16] Yao GH, Deng Y, Liu Y, et al. Echocardiographic measurements in normal chinese adults focusing on cardiac chambers and great arteries: a prospective, nationwide, and multicenter study. J Am Soc Echocardiogr 2015; 28: 570−579. doi: 10.1016/j.echo.2015.01.022 [17]

JIN WY, SHI XR, Chao YU, et al. Methodological comparison of left atrium classification according to the latest echocardiographic data from Chinese adults. Chin J Ultrasonogr 2019; 28: 7−11.

[18]

Garg A, Seeliger B, Derda A A. et al. Circulating cardiovascular microRNAs in critically ill COVID-19 patients. Eur J Heart Fail 2021; 23: 468−475.

[19] Stoica SC, Dorobantu DM, Vardeu A, et al. MicroRNAs as potential biomarkers in congenital heart surgery. J Thorac Cardiovasc Surg 2020; 159: 1532−1540.e1537. doi: 10.1016/j.jtcvs.2019.03.062 [20] Daniels SD, Meyer RA, Loggie JM. Determinants of cardiac involvement in children and adolescents with essential hypertension. Circulation 1990; 82: 1243−1248. doi: 10.1161/01.CIR.82.4.1243 [21] [22] Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation 1994; 90: 179−185. doi: 10.1161/01.CIR.90.1.179 [23] Zhao Y, Sun Q, Han J, et al. Left atrial stiffness index as a marker of early target organ damage in hypertension. Hypertens Res 2021; 44: 299−309. doi: 10.1038/s41440-020-00551-8 [24] Krishnan R, Mani P, Sivakumar P, et al. Expression and methylation of circulating microRNA-510 in essential hypertension. Hypertens Res 2017; 40: 361−363. doi: 10.1038/hr.2016.147 [25] Yang Q, Jia C, Wang P, et al. MicroRNA-505 identified from patients with essential hypertension impairs endothelial cell migration and tube formation. Int J Cardiol 2014; 177: 925−934. doi: 10.1016/j.ijcard.2014.09.204 [26] Lu X, Bi YW, Chen KB. Olmesartan restores the protective effect of remote ischemic perconditioning against myocardial ischemia/reperfusion injury in spontaneously hypertensive rats. Clinics (Sao Paulo) 2015; 70: 500−507. doi: 10.6061/clinics/2015(07)07 [27] Wang Y, Liang Y, Zhao W, et al. Circulating miRNA-21 as a diagnostic biomarker in elderly patients with type 2 cardiorenal syndrome. Sci Rep 2020; 10: 4894. doi: 10.1038/s41598-020-61836-z [28] Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011; 10: 430−439. doi: 10.1016/j.arr.2011.03.003 [29] Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380: 37−43. doi: 10.1016/S0140-6736(12)60240-2 [30] Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update. JACC Heart Fail 2017; 5: 543−551. doi: 10.1016/j.jchf.2017.04.012 [31] [32] Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49: 1774−1777. doi: 10.1038/ki.1996.265 [33] De Nicola L, Gabbai FB, Liberti ME, et al. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis 2014; 64: 16−24. doi: 10.1053/j.ajkd.2014.02.010 [34] Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990-2015. JAMA 2017; 317: 165−182. doi: 10.1001/jama.2016.19043 [35] Aeschbacher BC, Hutter D, Fuhrer J, et al. Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. Am J Hypertens 2001; 14: 106−113. doi: 10.1016/S0895-7061(00)01245-0 [36] Ibrahim EH, Dennison J, Frank L, et al. Diastolic cardiac function by MRI-imaging capabilities and clinical applications. Tomography 2021; 7: 893−914. doi: 10.3390/tomography7040075 [37] [38]

Landrier JF, Derghal A, Mounien L. MicroRNAs in obesity and related metabolic disorders. Cells 2019: 8.

[39] Doghish AS, Elsisi AM, Amin AI, et al. Circulating miR-148a-5p and miR-21-5p as novel diagnostic biomarkers in adult egyptian male patients with metabolic syndrome. Can J Diabetes 2021; 45: 614−618. doi: 10.1016/j.jcjd.2020.12.005 [40] Wang Y, Yang LZ, Yang DG, et al. MiR-21 antagomir improves insulin resistance and lipid metabolism disorder in streptozotocin-induced type 2 diabetes mellitus rats. Ann Palliat Med 2020; 9: 394−404. doi: 10.21037/apm.2020.02.28 [41]

Smith JD, Le Goff W, Settle M, et al. ABCA1 mediates concurrent cholesterol and phospholipid efflux to apolipoprotein A-I. J Lipid Res 2004; 45: 635−644.

[42] Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292−2300. doi: 10.1001/jama.290.17.2292 [43] Nicholls SJ, Puri R, Ballantyne CM, et al. Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I Milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial. JAMA Cardiol 2018; 3: 806−814. doi: 10.1001/jamacardio.2018.2112 [44] Didichenko SA, Navdaev AV, Cukier AM, et al. Enhanced HDL functionality in small HDL species produced upon remodeling of HDL by reconstituted HDL, CSL112: effects on cholesterol efflux, anti-inflammatory and antioxidative activity. Circ Res 2016; 119: 751−763. doi: 10.1161/CIRCRESAHA.116.308685 [45]

Chang WT, Hsu CH, Huang TL, et al. MicroRNA-21 is associated with the severity of right ventricular dysfunction in patients with hypoxia-induced pulmonary hypertension. Acta Cardiol Sin 2018; 34: 511−517.

[46]

Reddy S, Hu DQ, Zhao M, et al. miR-21 is associated with fibrosis and right ventricular failure. JCI Insight 2017; 2: 2:e91625.

[47]

Chang WT, Wu CC, Lin YW, et al. Dynamic changes in miR-21 regulate right ventricular dysfunction in congenital heart disease-related pulmonary arterial hypertension. Cells 2022: 11.

[48] Van Wezenbeek J, Kianzad A, Van De Bovenkamp A, et al. Right ventricular and right atrial function are less compromised in pulmonary hypertension secondary to heart failure with preserved ejection fraction: a comparison with pulmonary arterial hypertension with similar pressure overload. Circ Heart Fail 2022; 15: e008726. doi: 10.1161/CIRCHEARTFAILURE.121.008726

留言 (0)

沒有登入
gif